Brief: Sorrento Therapeutics Announces FDA IND Clearance Of STI-1558, An Oral M(Pro) And Cathepsin L Inhibitor To Treat Covid-19

Sorrento Therapeutics

19/07/2022 19:56

July 19 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO THERAPEUTICS ANNOUNCES THE FDA IND CLEARANCE OF
STI-1558, AN ORAL M(PRO) AND CATHEPSIN L INHIBITOR TO TREAT
COVID-19
    * SORRENTO THERAPEUTICS INC - FDA CLEARED IND APPLICATION
FOR
PHARMACOKINETIC (PK) STUDY IN PATIENTS WITH IMPAIRED RENAL AND
HEPATIC FUNCTION
    * SORRENTO THERAPEUTICS INC - STUDIES TO DATE INDICATE THAT
STI-1558 DOES NOT REQUIRE CO-ADMINISTRATION OF RITONAVIR AS A
BOOSTER FOR CYP3A4 INHIBITION
    * SORRENTO THERAPEUTICS- AS SOON AS SAD/MAD STUDY IS
COMPLETED, CO
WILL PREPARE FOR GLOBAL PHASE 2 STUDY IN SUBJECTS WITH ACUTE
ONSET OF SYMPTOMS DUE TO COVID

Source text for Eikon:  ID:nGNX8ccSlw 
Further company coverage:  SRNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))